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The development of new high-tech systems for screening anticancer drugs is one
of the main problems of preclinical screening. Poor correlation between preclinical
in vitro and in vivo data with clinical trials remains a major concern. The choice of
the correct tumor model at the stage of in vitro testing provides reduction in both
financial and time costs during later stages due to the timely screening of ineffective
agents. In view of the growing incidence of oncology, increasing the pace of the creation,
development and testing of new antitumor agents, the improvement and expansion of
new high-tech systems for preclinical in vitro screening is becoming very important. The
pharmaceutical industry presently relies on several widely used in vitro models, including
two-dimensional models, three-dimensional models, microfluidic systems, Boyden’s
chamber and models created using 3D bioprinting. This review outlines and describes
these tumor models including their use in research, in addition to their characteristics.
This review therefore gives an insight into in vitro based testing which is of interest to
researchers and clinicians from differing fields including pharmacy, preclinical studies
and cell biology.
Keywords: drug screening, two-dimensional cultures, three-dimensional cultures, microfluidic systems, Boyden
chamber, tumor microenvironment, 3D bioprinting
INTRODUCTION
The number of patients diagnosed with cancer is increasing worldwide and one of the most
important challenges remains the development of effective, safe and economically viable antitumor
drugs. Clinical approval for drugs tested in preclinical studies enabling them to enter phase I clinical
trials is essential. Currently, potential anticancer drugs have a very low rate of gaining clinical
approval at around 7%, much lower than drugs for other diseases (Hay et al., 2014). Given the high
cost and duration of anticancer drug clinical development it is necessary to develop new, more
effective preclinical platforms for screening antitumor compounds (Imamura et al., 2015).
In vitro tumor models are a necessary tool in not only the search for new substances showing
antitumor activity but additionally for assessing their effectiveness. Realistic in vitro models of
tumors enable more detailed primary screening of potential antitumor drugs thus preventing
drugs with insufficient antitumor activity from entering preclinical animal testing. Pharmacological
testing on animal models is carried out to assess bioavailability, toxicity at specific doses and
therapeutic efficacy of compounds (Stevens and Baker, 2009). According to industry standards, any
novel drugs must undergo preclinical trials using animal models before being admitted to human
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clinical trials. However, the use of animal models can cause a
number of problems including high cost, differential responses
due to physiological variations between species, and limitations
in test availability and feasibility (Bileckot et al., 1991). This
presents an opportunity and a requirement for the creation of
more high-tech in vitro models to assess the therapeutic efficacy
of antitumor drugs.
TUMOR MICROENVIRONMENT
The behavior of the tumor in the body is determined by cells
within the tumor and stromal tumor microenvironment (TME)
and the extracellular matrix (ECM), which provides structural
support for cells in the extracellular space (Chiantore et al.,
2015). The TME is characterized by a low extracellular pH
and a high level of hypoxia, both factors moderate dormant
phenotypes of tumor cells. As a result, these factors are associated
with development of therapy resistance and poor prognosis
of tumor-bearing patients (Peppicelli et al., 2017; Butturini
et al., 2019). The tumor biological characteristics are similar to
the chronically unhealed wound with constant inflammation,
which contributes toward tumorigenesis, tumor progression and
metastasis (Gal et al., 2017). Attracted by the tumor stromal
microenvironment, other cell types also play a key role in not
only tumor progression and metastasis, but also in the formation
of resistance to therapies (Wu and Dai, 2017). Within the TME
many other cellular components reside including immune cells
(T-lymphocytes, B-lymphocytes, neutrophils, natural killer cells
(NK-cells) and macrophages), endothelial cells associated with
the tumor, fibroblasts, myofibroblasts, adipocytes, pericytes and
mesenchymal stem/stromal cells (MSCs) (Chiantore et al., 2015).
The stromal cells and fibroblasts within the TME are known
to secrete growth factors and chemokines, which support the
growth and survival of malignant cells and additionally function
as chemoattractants that stimulate the migration of other cells
into the tumor (Hanahan and Coussens, 2012). MSCs are
involved throughout every stage of tumor development: avoiding
immunological surveillance, stimulating tumor angiogenesis,
developing resistance to therapy, invasion and metastasis, as well
as inducing the transition of tumor cells into a low-differentiated
state and the formation of stem tumor cells (Sun et al., 2014). Of
great interest is the interaction between immune cells and tumor
cells, this is primarily due to the dual role of immune cells and the
factors they produce. Immune reactions prevent and inhibit the
development of tumors, however, recent evidence suggests that
immune cells in the tumor microenvironment closely interact
with transformed malignant cells, thus promoting oncogenesis
(Payne et al., 2014).
An important component of TME is the ECM, consisting
of components with various physical and biochemical
properties, including proteins, glycoproteins, proteoglycans
and polysaccharides (Insua-Rodriguez and Oskarsson, 2016).
ECM provides physical support for TME cells, and also it
is a source of key growth factors. In the late stages of the
ECM become disorganized. ECM modulates the behavior of
stromal cells in the tumor microenvironment, which leads to
the induction of inflammatory reactions and the growth of new
blood vessels (Trivanovic et al., 2016).
Thus, the study of the tumor as a complex environment
can make a significant contribution to improving the quality
of cancer treatment, as can the development of new diagnosis
and personalized therapeutic methodologies (Chulpanova et al.,
2018a,b,c), alongside the creation of new, realistic tumor models
for the effective screening of new substances exhibiting potential
antitumor activity.
TWO-DIMENSIONAL CULTURES
Until the 1980s, the National Cancer Institute (NCI) used in vivo
mouse models of P388 or L1210V leukemia for systematic
screening of drugs (Waud, 2011). These models possessed high
levels of productivity and stability, were convenient for data
interpretation, and were relatively inexpensive. Despite these
qualities, a significant drawback to these models was the inability
to identify potential antitumor substances aimed at treating solid
tumors. This drawback was taken into account, and by the end
of the 80s, an in vitro panel for drug screening was developed,
consisting of 60 different human cell lines originating from
tumors (leukemia, melanoma, tumors of the central nervous
system, cancer of the lungs, colon, ovaries, breast, kidney, and
prostate), which was called NCI60 (Mingaleeva et al., 2013).
Testing a drug of interest using the NCI60 panel involves
the application of two-dimensional (2D) tumor cell cultures,
grown in a monolayer on a flat surface (Takimoto, 2003). During
the first stage of screening, testing is carried out on the three
cell lines that are frequently the most sensitive to drug therapy,
MCF7 (breast adenocarcinoma), NCI-H460 (lung carcinoma)
and SF-268 (glioma) (Blatt et al., 2013). The cytotoxicity of
the test substance is determined using the pink anionic dye
sulforodamine B. If the test substance inhibits the growth of at
least one cell line, testing proceeds to the next stage comprising
of the full 60 cell line panel (Mingaleeva et al., 2013). In 2017,
the NCI ALMANAC database was created based on screening
results using the NCI60 panel1. The database helped identify
new effective combinations of existing antitumor drugs and new
clinical trials were launched (Holbeck et al., 2017).
By analogy with the NCI60 panel, the Japanese Foundation
for Cancer Research (JFCR) developed a panel in the 1990s
consisting of 30 tumor lines from the NCI60 panel, plus nine
tumor cells lines specific to the Japanese population, specifically
gastric cancer cells (St-4, MKN-1, MKN-7, MKN-28, MKN-45,
and MKN-74) and breast cancer cells (HBC-4, HBC-5, and
BSY-1). Thus, the panel included 39 cell lines and was therefore
called JFCR39 (Nakatsu et al., 2007). However, during clinical
trials, it became apparent that drugs that have shown high
efficacy in 2D in vitro models do not always work or can have
a low efficacy in oncology patients (Shoemaker, 2006). This
phenomenon is partially explained by the fact that cells grown
in 2D cultures do not have a complex three-dimensional tissue
architecture and do not exactly reflect the complex interactions
1https://dtp.cancer.gov/ncialmanac
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FIGURE 1 | Different types of in vitro tumor models. (A) Two-dimensional cell cultures based on monolayer (1) consisting of tumor cells (2) co-culture included tumor
and stromal cells. (B) The Boyden chamber scheme, analyzing the ability of cells to migrate – cells with high invasive potential pass through the porous membrane.
(C) Three-dimensional cellular models based on multicellular spheroids/organoids: (1) spheroids consisting of tumor cells (2) a tumor stroma model based on the
co-cultivation of several types of cells on extracellular matrix model model or on the organoid-based manner (3) spheroids created using the hanging drops method.
(D) Scheme of microfluidic system that evaluates the invasive potential of tumor cells – a mixture of hydrogel and cells is placed in the central channel, into the lateral
channels placed the enriched/depleted factors medium depending on the purpose of the experiment. (E) Tumor bioprinting models (1) a tumor model, which is a
layer of tumor cells located between the layers of stromal cells (2) bioprinted spheroids consisting of tumor cells (3) bioprinted spheroids, which are a model of the
tumor stroma, consisting of tumor cells mixed with stromal cells (4) a glioma model, consisting of conventional 3D-printed model of the brain with glioma cells and
macrophages embedded in.
between TME or ECM and cells which exist in the body
(Figure 1A; Rizvanov et al., 2010).
BOYDEN CHAMBER
The Boyden chamber is a chamber consisting of two
compartments filled with medium and separated by a
microporous membrane (Falasca et al., 2011). Boyden chamber
is a convenient tool for the study of chemotaxis, assessing cell
motility and invasion (Figure 1B). Thus, the Boyden chamber
was used to assess cell motility in a study on the effect of
free paclitaxel and paclitaxel-loaded pyromellitic nanorods
on reducing the growth and invasiveness of melanoma cells
(Clemente et al., 2019). Wessely et al. (2019) also tested the
use of the Boyden chamber to evaluate and compare the
invasive activity of spheroids containing only tumor cells and
spheroids containing a mixture of tumor and stem cells. Another
study examined the adhesion and cytoskeletal migration of
HT1080 fibrosarcoma cells and LX2 line stellate cells in a
three-dimensional system using fibronectin, Matrigel and type
I collagen as chemoattractants (Tovari et al., 2014). However,
despite the ease of use of the Boyden chamber, researchers are
increasingly turning to more advanced systems that take into
account a greater number of TME conditions, in particular,
microfluidic systems.
THREE-DIMENSIONAL CULTURES
It is known that 2D cultures do not fully reflect the
pathophysiology of tumor cells and the actual level of resistance
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TABLE 1 | Comparative characteristics of cell culture test systems for anticancer drug screening.
Tumor model Advantages Disadvantages Application Cell type References
Two-dimensional
mono cell cultures
Simple test system for rapid
cost effective screening of
multiple compounds or libraries
Do not have a complex
three-dimensional tissue
architecture, complex
interactions between TME
or ECM and cells
Anticancer drug screening NCI60 panel (Shoemaker, 2006)
JFCR39 panel (Nakatsu et al., 2007)
Boyden’s chamber Possibility to study the effect of
the test substance on the
invasiveness and migration
potential of tumor cells
The lack of direct
intercellular interactions (the
study of paracrine factors
only) important for TME
Chemotaxis, assessing cell
motility and invasion studies
2D cultures (melanoma,
fibrosarcoma and other cell types)
(Tovari et al., 2014;
Clemente et al., 2019)
Spheroids (tumor or tumor and
stem cells)
(Kaneda et al., 2019;
Wessely et al., 2019)
Microfluidic
systems
Can reproduce a specific fluid
flow, constant temperature, flow
pressure and chemical gradients
characteristic of in vivo systems
Expensive consumables
and equipment,
non-standardized protocols
Migration/invasion and
extravasation studies
2D cultures (lung
adenocarcinoma cells, breast
tumor cells and other cell types
(Chen et al., 2010; Wang
et al., 2013; Anguiano
et al., 2017)
Co-culture (CAFs + NSCLC cells) (Yu et al., 2016)
Breast or liver cancer spheroids (Yu et al., 2010; Zuchowska
et al., 2017)
Three-dimensional
spheroids
Can reproduce paracrine and
direct intercellular interaction,
complex three-dimensional
architecture and hypoxic
conditions in the center of the
spheroid
Do not accurately
reproduce interaction
between ECM and cells.
Difficult to standardize.
Anticancer drug screening,
invasion studies
One cell type (breast, liver cancer
cells, head and neck squamous
cell carcinoma and other cell
types)
(Uchida et al., 2010;
Imamura et al., 2015;
Melissaridou et al., 2019)
Several cell types (colorectal
carcinoma+ fibroblasts/endothelial
cells)
(Zoetemelk et al., 2019)
Three-dimensional
organoids
Accurately reproduce in vivo
tumor architecture
Difficulty in creating large
numbers of homogeneous
organoids for
high-throughput drug
screening
Anticancer drug screening,
invasion and extravasation
studies
Organoids derived from lung
cancer/prostate cancer bone
metastasis/bladder cancer
tissues
(Kim et al., 2019;
Mullenders et al., 2019;
Nelson et al., 2020)
Cerebral glioma/medulloblastoma
organoids derived from induced
pluripotent stem cells (iPSCs)
(Linkous et al., 2019;
Ballabio et al., 2020)
Colon cancer organoids derived
from cancer stem cells (CSCs)
(Otte et al., 2019)
Co-cultures on
scaffolds
Complex three-dimensional
tissue architecture, complex
interactions between TME or
ECM and cells
Poor reproducibility and
similarity to in vivo tumor
architecture
Anticancer drug screening,
invasion studies, cell
infiltration studies
Co-culture of NSCLC
cells + fibroblasts + immune
cells on Matrigel
(Osswald et al., 2019)
Co-culture of PDAC cell
lines + CAFs surrounding by
oligomeric type I collagen
(Puls et al., 2018)
(Continued)
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to radiotherapy or chemotherapy in the tumor niche in the
in vivo system (Chen et al., 2012; Table 1). Studies have shown
that gene expression profiles as well as treatment responses in
multicellular spheroid 3D models are more similar to the in vivo
situation (Riedl et al., 2017). For example, liver tumor cells in
3D culture have high resistance to drug treatment, similar to the
resistance of solid tumors in vivo (Uchida et al., 2010). Thus, the
BT-549, BT-474, and T-47D breast cancer cell lines cultured as
spheroids showed greater resistance to paclitaxel and doxorubicin
compared to cells in a 2D culture (Imamura et al., 2015). Cells
of squamous cell carcinoma originating from the head and neck
(lines LK0902, LK0917, and LK1108) cultured as spheroids were
shown to be less sensitivity to cisplatin when compared with
2D cultures. Also in cell lines LK0917 and LK1108, resistance to
cetuximab was observed, mediated by culturing in the form of
spheroids (Melissaridou et al., 2019). When culturing HCT-116,
SW-620, and DLD-1 cells in the form of spheroids or in co-
culture with fibroblasts and endothelial cells, their resistance to
5-fluorouracil, regorafenib, and erlotinib preparations increases
(Zoetemelk et al., 2019).
It is known that the TME may significantly change the
susceptibility of tumor cells to drugs. To solve this problem,
new methods were developed for culturing cells using the ECM
to model spatial organization, as well as adding various types
of cells included in the TME to the culture (Kitaeva et al.,
2019). 3D co-cultures of non-small cell lung cancer (NSCLC) and
fibroblasts embedded in a Matrigel or encapsulated in alginate
are used as models in drug discovery for analysis of immune
cell infiltration (Osswald et al., 2019). Also, described is a high-
potential tumor spheroid model drug screening, which consists of
pancreatic ductal adenocarcinoma (PDAC) cell lines (Panc-1 and
BxPC-3) and cancer-associated fibroblasts (CAFs) surrounding
by oligomeric type I collagen (Oligomer) for creation of the
interstitial ECM supports definition (Puls et al., 2018).
An alternative way to create a novel 3D tumor-tissue model
is organoid manner. One of the first of developed spheroid
method was a mammospheres, described Dontu et al. (2003).
The novel in vitro system allowed the propagation of mammary
stem and progenitor cells into functional ductal/acinar structures
(Dontu et al., 2003). Organoids can be received by two main
types of stem cells: pluripotent embryonic stem cells and their
synthetic induced pluripotent stem cell counterparts and organ-
restricted adult stem cells (Clevers, 2016). Also, organoids
received by cultivation small tissue fragments and explants
on matrixes or from cultured or sorted cells assembled to
organoids in vitro (Hu et al., 2018). Organoids from primary
lung cancer tissues demonstrated the high reproduction levels of
histological and genetic characteristics of in situ tissue and their
high ability for using them in patient-specific drug trials (Kim
et al., 2019). Organoid manner was used for modeling PDAC
from patient derived xenografts (PDX) tumors (Nelson et al.,
2020) and organoids derived from patient prostate cancer bone
metastasis (Lee et al., 2020). Organoids derived from patients
with bladder cancer were tested with epirubicin, mitomycin C,
gemcitabine, vincristine, doxorubicin, and cisplatin, this model
was presented as a prospective model of human bladder cancer
(Mullenders et al., 2019; Figure 1C).
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MICROFLUIDIC SYSTEMS
Microfluidic systems are prospective models for reconstructing
the migration, microenvironment, and microcirculation of cells
in tumor tissue. Microfluidic systems are small devices that
can reproduce a specific fluid flow, constant temperature, fresh
medium, flow pressure and chemical gradients characteristic of
in vivo systems (Ruzycka et al., 2019; Figure 1D).
The microfluidic system using collagen-matrigel hydrogel
matrices made it possible to reproduce the microenvironment
and experimental conditions for studying the migration and
invasion of H1299 lung adenocarcinoma cells. At the same
time, Matrigel in low concentrations facilitated the migration of
H1299 cells, however, at a high concentration Matrigel slowed
the migration of cells, possibly due to their excessive attachment.
It has also been shown that the use of antibody-based integrin
blockers significantly modulated the mechanisms of H1299 cell
migration (Anguiano et al., 2017). A microfluidic system with an
incessant supply of nutrient medium through a syringe pump
has also been described. It is used to study the effect of the
matrix metalloproteinase inhibitor (GM6001) on the formation
of invadopodia in A549 lung cancer cells, which is characteristic
of cells during invasion (Wang et al., 2013). Microfluidic systems
also make it possible to obtain a metastatic model of a tumor,
such as breast cancer, which allows the study of antitumor drugs
effects on the inhibition of tumor cell migration (Mi et al.,
2016). To simulate the extravasation process, a microfluidic
system was constructed containing two microfluidic channels
and a porous membrane sandwiched between them. The first
channel represents the vascular equivalent and contains primary
endothelial cells isolated from the pulmonary artery. The second
channel acts as a reservoir for collecting migratory tumor cells.
In this case, endothelial cells showed in vivo-like behavior
under flow conditions. The introduced GFP-labeled tumor cells
of epithelial or mesenchymal origin were detected using vital
imaging, which showed tightly attached tumor cells to the
endothelial membrane (Kuhlbach et al., 2018).
3D BIOPRINTING
One of the types of three-dimensional cultures is 3D bioprinting,
which enables researchers to create various situations that mimic
the processes that occur in the TME (Lee et al., 2016; Truong
et al., 2018). 3D bioprinting technology enables the creation
of standardized test-systems for screening anticancer drugs
(Kingsley et al., 2019; Figure 1E). For example, a model of human
hepatoma created using 3D bioprinting was more resistant to an
anti-CD147 monoclonal antibody (Metuzumab) than a similar
model created on a microfluidic system (Li et al., 2019).
An interesting approach is the combination of several types of
cells, tumor and stromal, in a 3D bioprinting model. Breast cancer
cells and fibroblasts cultured in 3D bioprinting spheroids as part
of an alginate-gelatin hydrogel maintained viability for more than
30 days and were resistant to paclitaxel, which was not observed
in 3D bioprinting monocultures of breast cancer cells (Jiang et al.,
2018). The trophic role of stromal or immune cells has been
shown in other studies. The presence of MSCs in 3D bioprinting
hydrogel constructs supported breast cancer cell viability after
exposure of doxorubicin (Wang et al., 2018). Application of
3D bioprinting technology also allows immune cell behavior
studies in TME. In a 3D bioprinting model, glioblastoma cells
were shown to actively recruit macrophages and polarize them
in glioblastoma-associated macrophages (GAMs), which in turn
contributed to the proliferation and invasiveness of glioblastoma
cells (Heinrich et al., 2019). 3D-bioprinting models of breast and
pancreatic cancer containing the stromal component (human
umbilical vessel epithelial cells (HUVEC), fibroblasts, MSCs) and
an ECM analog were described. The resulting 3D bioprinting
models repeated the behavior of tumors in vivo and in situ
(Langer et al., 2019).
The using of 3D bioprinting also enables designs that simulate
tumor vascularization. 3D organotypic microfluidic platform,
integrated with hydrogel biomaterials, were obtained in order
to simulate the vascular niche of glioma stem cells (GSCs)
obtained from patients (Truong et al., 2018). It has been shown
that the microvascular network enhances invasion, supports the
proliferation rate and the classic GSCs phenotype (Truong et al.,
2018). A three-dimensional model of GSCs is described in the
composition of a porous hydrogel containing gelatin, alginate
and fibrinogen. GSCs actively proliferated, retained viability and
biological properties (nestin expression, differentiation ability)
in the resulting 3D bioprinting in vitro model, and also had
resistance to the cytotoxic effect of temozolomide in contrast to
2D culture. An increase in vascular endothelial growth factor
(VEGF) secretion in the first 3 weeks of cultivation was also
noted, which indicates the induction of tumor angiogenesis
mechanisms (Dai et al., 2016). 3D bioprinting capsules with
programmable VEGF and EGF outputs also mimics tumor
vascularization. The programmed release of growth factors
facilitates control over cell migration and the process of
angiogenesis, therefore it is possible to get a dynamic system for
the study of metastatic processes (Meng et al., 2019).
Thus, the designs obtained using 3D bioprinting enable us
to simulate various processes occurring in TME. Further studies
in the field of 3D bioprinting, standardization and validation
of the developed tumor models will allow the creation of high-
efficiency 3D tumor models in order to obtain new fundamental
knowledge about the mechanisms of carcinogenesis and also
to more accurately screen potential anticancer drugs and aid
individual selection of drugs (Knowlton et al., 2015).
CONCLUSION
In recent decades, preclinical trials of antitumor agents have
undergone significant changes, in particular, much attention has
been focused on the modernization of screening protocols for
cell cultures. The widespread use of in vitro models in preclinical
practice was facilitated by the development of the NCI60 panel.
Even after more than 30 years, this model is still actively used
for screening anticancer drugs as a reference in vitro testing
method. However, as knowledge of intercellular interactions
within the tumor deepened, as well as the low reliability of testing
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potential anticancer drugs on the NCI60 panel, in the field of
preclinical screening, the need arose to develop more complex
and high-tech models. Three-dimensional cultures, representing
spheroids and spheroid-like formations grown under various
cultivation conditions, partially satisfied this request. Three-
dimensional cultures compensated for some of the shortcomings
of two-dimensional cultures, in particular those associated with
intercellular interactions and interactions with the extracellular
scaffold. However, conventional three-dimensional cultures are
not quite suitable for assessing the effect of anticancer drugs on
important processes as migration, invasion and chemotaxis; such
studies require the use of additional devices, for example, chips
in microfluidic systems and the Boyden chamber. One of the
trends of the last decade has been the use of 3D bioprinting,
thanks to which, in theory, it is possible to print fabric with the
desired architecture with a sufficiently high resolution. Although
at the moment there is no universal protocol for printing this
or a standard type of tumor tissue used with it, interest in this
technology and the importance of its further development are not
weakening. Researchers working in the developing new screening
models field may liken the situation to the Greek mythology of
Odysseus, finding themselves between Scylla and Charybdis –
when the model must be complex enough to take into account
most of the microenvironment factors, but at the same time be
reproducible, with the ability to correctly interpret the screening
results. Existing trends in science, particularly in the field of
preclinical screening, are heading precisely toward complicating
the models being developed, drawing an analogy, the course for
Scylla, which turned out to be a competent choice for Odysseus.
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